FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients

被引:10
|
作者
Georgina Turcott, Jenny [1 ]
Onate-Ocana, Luis F. [2 ]
Soca-Chafre, Giovanny [3 ]
Ramirez-Tirado, Laura-Alejandra [3 ]
Flores-Estrada, Diana [1 ]
Lucia Zatarain-Barron, Zyanya [1 ]
Arrieta, Oscar [1 ]
机构
[1] Natl Canc Inst Mexico INCan, Thorac Oncol Unit, Mexico City, DF, Mexico
[2] Natl Canc Inst Mexico INCan, Div Surg, Clin Res Div, Mexico City, DF, Mexico
[3] Natl Canc Inst Mexico INCan, Expt Oncol Lab, Mexico City, DF, Mexico
来源
关键词
QUALITY-OF-LIFE; NUTRITIONAL-STATUS; ASSOCIATION; VALIDATION; ANAMORELIN; PROGNOSIS; THERAPY; DISEASE; IMPACT;
D O I
10.1080/01635581.2018.1506488
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer (LC) has a high rate of anorexia, which negatively affects quality-of-life and prognosis; however prevalence values may vary as per diagnostic test. There is no standard for anorexia diagnosis, currently the anorexia cachexia scale (A/CS) has been proposed as a tool for diagnosing anorexia with a consensus cutoff value of <= 24, nonetheless a validated cutoff value is required. The A/CS was evaluated in advanced Non-Small Cell Lung Cancer (NSCLC) patients to establish a cutoff value. The appetite item from the QLQ-C30 questionnaire and survival served as a standard reference. The cutoff value was associated with clinical and nutritional characteristics along with quality-of-life. Three hundred and twelve (312) NSCLC patients were evaluated. The mean A/CS value was 31 +/- 9 and the identified cutoff value was 32.5 (sensitivity: 80.3% and specificity: 85%). The proportion of anorexia accurately diagnosed with the cutoff value of 24 was 26%, while with 32 it was 50%. The A/CS cutoff value of 32 was associated with clinical parameters, nutritional consumption, and quality-of-life, and independently associated with overall survival. A score of <= 32 in the A/CS is proposed for anorexia diagnosis in order to identify patients at risk of complications involving malnutrition related to LC.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 50 条
  • [21] Erlotinib Plus Parenteral Nutrition: An Opportunity to Get Through the Hardest Days of Advanced Non-Small Cell Lung Cancer With Cancer Anorexia-Cachexia Syndrome
    Zang, Yuan-Sheng
    Fang, Zheng
    Li, Bing
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2013, 30 (02): : 210 - 213
  • [22] CLINICAL MANAGEMENT OF ANOREXIA AND CACHEXIA IN PATIENTS WITH ADVANCED CANCER
    BRUERA, E
    ONCOLOGY, 1992, 49 : 35 - 42
  • [23] Body weight response with anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia: Pooled analysis of two phase III trials.
    Currow, David Christopher
    Temel, Jennifer S.
    Abernethy, Amy Pickar
    Friend, John
    Giorgino, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer—chemotherapy toxicity and prognostic value
    Drazena Srdic
    Sanja Plestina
    Ana Sverko-Peternac
    Nora Nikolac
    Ana-Maria Simundic
    Miroslav Samarzija
    Supportive Care in Cancer, 2016, 24 : 4495 - 4502
  • [25] EVALUATION OF ANOREXIA-CACHEXIA SYMPTOMS/CONCERNS FROM ROMANA 2, A PHASE III TRIAL OF ANAMORELIN IN NON-SMALL CELL LUNG CANCER PATIENTS WITH CACHEXIA.
    Brewer, Cheryl
    Abernethy, Amy
    Currow, David
    Fearon, Kenneth
    Friend, John
    Temel, Jennifer
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E229 - E229
  • [26] Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
    Jo, Hitomi
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Yagishita, Shigehiro
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Yamamoto, Noboru
    Takahashi, Kazuhisa
    Motoi, Noriko
    Ohe, Yuichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (02) : 387 - 398
  • [27] Assessment of anorexia and weight loss in newly diagnosed upper gastrointestinal cancer patients with localised and metastatic disease, using the functional assessment of anorexia cachexia therapy anorexia/cachexia subscale (FAACT A/CS)
    Abraham, M.
    Kordatou, Z.
    Mansoor, W.
    ANNALS OF ONCOLOGY, 2018, 29 : 617 - 617
  • [28] Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
    Hitomi Jo
    Tatsuya Yoshida
    Hidehito Horinouchi
    Shigehiro Yagishita
    Yuji Matsumoto
    Yuki Shinno
    Yusuke Okuma
    Yasushi Goto
    Noboru Yamamoto
    Kazuhisa Takahashi
    Noriko Motoi
    Yuichiro Ohe
    Cancer Immunology, Immunotherapy, 2022, 71 : 387 - 398
  • [29] Correlation Between the International Consensus Definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and Patient-Centered Outcomes in Advanced Non-Small Cell Lung Cancer
    LeBlanc, Thomas W.
    Nipp, Ryan D.
    Rushing, Christel N.
    Samsa, Greg P.
    Locke, Susan C.
    Kamal, Arif H.
    Cella, David F.
    Abernethy, Amy P.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 49 (04) : 680 - 689
  • [30] Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia A Randomized Clinical Trial
    Arrieta, Oscar
    Cardenas-Fernandez, Daniela
    Rodriguez-Mayoral, Oscar
    Gutierrez-Torres, Salvador
    Castanares, Diana
    Flores-Estrada, Diana
    Reyes, Edgar
    Lopez, Dennis
    Barragan, Pablo
    Soberanis Pina, Pamela
    Cardona, Andres F.
    Turcott, Jenny G.
    JAMA ONCOLOGY, 2024, 10 (03) : 305 - 314